Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Pinter

Showing results (111-120 of 135) with videos related to

Pageof 14
Sort By:
American Journal of Clinical Dermatology|March 28, 2026
Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic DermatitisAmy S Paller, Eric L Simpson, Elaine C Siegfried, et al.
Dermatology and Therapy|January 17, 2025
Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) StudyRichard B Warren, Lev Pavlovsky, Antonio Costanzo, et al.
Dermatology and Therapy|November 8, 2024
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) StudyRichard B Warren, Lev Pavlovsky, Antonio Costanzo, et al.
Journal of the American Academy of Dermatology|May 23, 2026
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD StudyJennifer Soung, Yong Cui, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|March 25, 2026
Impact of early treatment of psoriasis on disease recurrence - Results from the STEPIn studyLars Iversen, Richard G Langley, Johann E Gudjonsson, et al.
Zeitschrift Fur Rheumatologie|January 4, 2023
[Immune-mediated inflammatory diseases in Germany : A cross-sectional analysis of comorbidities and pharmacotherapy]Jan Leipe, Renate Schmelz, Gabriela Riemekasten, et al.
Lancet (London, England)|July 21, 2024
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trialsRobert Bissonnette, Richard B Warren, Andreas Pinter, et al.
Lancet (London, England)|April 12, 2025
Reflections on chronic hand eczema - Authors' replyRobert Bissonnette, Richard B Warren, Andreas Pinter, et al.
The British Journal of Dermatology|August 10, 2023
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD studyJoseph F Merola, Albert S Chiou, Emmanuel During, et al.
The British Journal of Dermatology|July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
Pageof 14

Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
American Journal of Clinical Dermatology|March 28, 2026
Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic DermatitisAmy S Paller, Eric L Simpson, Elaine C Siegfried, et al.
Dermatology and Therapy|January 17, 2025
Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) StudyRichard B Warren, Lev Pavlovsky, Antonio Costanzo, et al.
Dermatology and Therapy|November 8, 2024
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) StudyRichard B Warren, Lev Pavlovsky, Antonio Costanzo, et al.
Journal of the American Academy of Dermatology|May 23, 2026
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD StudyJennifer Soung, Yong Cui, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|March 25, 2026
Impact of early treatment of psoriasis on disease recurrence - Results from the STEPIn studyLars Iversen, Richard G Langley, Johann E Gudjonsson, et al.
Zeitschrift Fur Rheumatologie|January 4, 2023
[Immune-mediated inflammatory diseases in Germany : A cross-sectional analysis of comorbidities and pharmacotherapy]Jan Leipe, Renate Schmelz, Gabriela Riemekasten, et al.
Lancet (London, England)|July 21, 2024
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trialsRobert Bissonnette, Richard B Warren, Andreas Pinter, et al.
Lancet (London, England)|April 12, 2025
Reflections on chronic hand eczema - Authors' replyRobert Bissonnette, Richard B Warren, Andreas Pinter, et al.
The British Journal of Dermatology|August 10, 2023
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD studyJoseph F Merola, Albert S Chiou, Emmanuel During, et al.
The British Journal of Dermatology|July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
Pageof 14